Parallax Volatility Advisers
MRNS

Parallax Volatility Advisers’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Parallax Volatility Advisers’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,700
Closed -$115K – 2335
2024
Q1 		$115K Buy
+12,700
New +$123K ﹤0.01% 1594
2023
Q1 		– Sell
-10,292
Closed -$64.5K – 3298
2022
Q4 		$41K Sell
10,292
-50,577
-83% -$249K ﹤0.01% 2393
2022
Q3 		$405K Buy
+60,869
New +$375K ﹤0.01% 2057
2019
Q3 		– Sell
-19,323
Closed -$321K – 3691
2019
Q2 		$321K Sell
19,323
-2,325
-11% -$40.4K ﹤0.01% 1623
2019
Q1 		$362K Buy
21,648
+20,471
+1,739% +$295K ﹤0.01% 1642
2018
Q4 		$14K Buy
+1,177
New +$23.8K ﹤0.01% 2460

Other funds holding MRNS

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Parallax Volatility Advisers's MRNS Position: Q2 2024 in Review

Parallax Volatility Advisers sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 12,700 shares — an estimated $115K sold.

Parallax Volatility Advisers first reported a position in MRNS in Q4 2018 and held it in 6 quarters. The position peaked at $405K in Q3 2022. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

  • Parallax Volatility Advisers reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
  • Parallax Volatility Advisers sold 12,700 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $115K.
  • Parallax Volatility Advisers first reported a position in Marinus Pharmaceuticals, Inc in Q4 2018 and held it in 6 quarters.
  • Parallax Volatility Advisers's Marinus Pharmaceuticals, Inc position peaked at $405K in Q3 2022.
  • 90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on Parallax Volatility Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.